Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can
become chronic and lead to increased death rates and disease severity. Studies from cystic
fibrosis suggest that eradication therapy aimed at PA can successfully transition patients to
a culture-negative status, providing long-term benefits. Current guidelines for managing
bronchiectasis in adults recommend eradicating PA when it is first or newly isolated;
however, there is a lack of randomized controlled trials supporting such recommendations. The
researchers hypothesize that both oral ciprofloxacin combined with Tobramycin inhalation
solution and Tobramycin inhalation solution alone are superior to no eradication (inhaled
saline) in terms of the eradication rates of PA, defined as a negative sputum culture of PA
at both 24 weeks and 36 weeks.